Thermo Fisher Scientific Inc. · Healthcare
The price already needs more growth than analysts forecast, at both a 9% and an 8% discount rate.
At a 18.0% margin the price requires 13.2% 3y revenue CAGR against 6.7% consensus, a cushion of -13.9pt versus a 1pt correction cut. Price needs more growth than consensus at any nearby discount rate, so the correction has room to go further. Priced for acceleration that consensus doesn't show; small customer channel.
Would recover if: pharma/biotech demand stays at 6.7% growth. We re-check this against analyst estimates every evening.
10 years, at a 18% margin analysts expect
+5.0%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
11 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 126% of reported profit arrived as operating cash, so the analysts' margin stands.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 24, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits 11% above the median published target and at the 82nd percentile of the model spread, meaning it leans bullish and already pays for a growth acceleration that the company has not yet delivered.
Can Thermo Fisher's organic revenue growth actually accelerate from the mid-single-digits delivered in early 2026 toward the 16.5% CAGR the current price requires, and the available wired data (unit_volumes via segment revenue history) can measure whether this acceleration is happening quarter by quarter.
What the price refuses to pay for, and the full reconstruction, on the TMO quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names